Twenty years of progress with parathyroid hormone (PTH): From specialized and "difficult" measurement to common laboratory parameter and treatment option in osteoporosis

Clinical Laboratory

Volumn 54, Issue 11-12, 2008, Pages 439-449

  Blind, Eberhard ^a,b  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ADD ON THERAPY; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; ECTOPIC HORMONE PRODUCTION; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; IMMUNOASSAY; NONHUMAN; OSTEOPOROSIS; PARATHYROID CARCINOMA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; VERTEBRA FRACTURE;

AMINO ACID SEQUENCE; BONE DENSITY; CALCIUM; CLINICAL CHEMISTRY TESTS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; OSTEOPOROSIS; PARATHYROID HORMONE; RADIOIMMUNOASSAY;

EID: 60549085532     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Schmidt-Gayk H, Hüfner M, Haueisen H, Stengel R. [Measurement of parathormone (PTH) and cyclic AMP (c AMP) in 50 patients with primary hyperparathyroidism (1st degree HPT)]. Verh Dtsch Ges Inn Med. 1976;82 Pt 2:1888-1890.
2. Hitzler W, Schmidt-Gayk H, Spiropoulos P, Raue F, Hüfner M. Homologous radioimmunoassay for human parathyrin (residues 53-84). Clin Chem. 1982;28:1749-1753.
3. Schmidt-Gayk H, Schmitt-Fiebig M, Hitzler W, Armbruster FP, Mayer E. Two homologous radioimmunoassays for parathyrin compared and applied to disorders of calcium metabolism. Clin Chem. 1986;32:57-62.
4. Armitage EK. Parathyrin (parathyroid hormone): metabolism and methods for assay. Clin Chem. 1986;32:418-424.
5. Brown RC, Aston JP, Weeks I, Woodhead JS. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab. 1987;65:407-414.
6. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, et. al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987;33: 1364-1367.
7. Blind E, Schmidt-Gayk H, Armbruster FP, Stadler A. Measurement of intact human parathyrin by an extracting two-site immunoradiometric assay. Clin Chem. 1987;33:1376-1381.
8. Blind E, Schmidt-Gayk H, Scharla S et al. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay. J Clin Endocrinol Metab. 1988;67:353-360.
9. Ratcliffe WA, Heath DA, Ryan M, Jones SR. Performance and diagnostic application of a two-site immunoradiometric assay for parathyrin in serum. Clin Chem. 1989;35:1957-1961.
10. Bouillon R, Coopmans W, Degroote DE, Radoux D, Eliard PH. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem. 1990;36: 271-276.
11. Klee GG, Preissner CM, Schryver PG, Taylor RL, Kao PC. Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin. Clin Chem. 1992;38:628-635.
12. Soldin OP, Dahlin JR, Gresham EG, King J, Soldin SJ. IMMULITE 2000 age and sex-specific reference intervals for alpha fetoprotein, homocysteine, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, C-peptide, immunoglobulin E and intact parathyroid hormone. Clin Biochem. 2008;41:937-942.
13. Martin KJ, Olgaard K, Coburn JW et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004;43:558-565.
14. Gao P, D'Amour P. Evolution of the parathyroid hormone (PTH) assay-importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab. 2005;51:21-29.
15. Huan J, Olgaard K, Nielsen LB, Lewin E. Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol. 2006;17:1923-1930.
16. Nemeth EF. The parathyroid polyhormone hypothesis revisited. Kidney Int Suppl. 2006;S22-8.
17. Carnevale V, Dionisi S, Nofroni I et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem. 2004; 50:626-631.
18. Jüppner H, Potts JTJ. Immunoassays for the detection of parathyroid hormone. J Bone Miner Res. 2002;17 Suppl 2:N81-6.
19. Lehmann G, Stein G, Huller M, Schemer R, Ramakrishnan K, Goodman WG. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68:1206-1214.
20. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant. 2003;18:759-768.
21. Roth HJ, Albert C, Schmidt-Gayk H. New assays for intact parathyroid hormone and their clinical relevance for the diagnosis of hyperparathyroidism. Clin Lab. 2002;48:589-593.
22. Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta. 2006;366:81-89.
23. Waller S, Ridout D, Cantor T, Rees L. Differences between "intact" PTH and 1-84 PTH assays in chronic renal failure and dialysis. Pediatr Nephrol. 2005;20:197-199.
24. Levin GE, Nisbet JA. Stability of parathyroid hormone-related protein and parathyroid hormone at room temperature. Ann Clin Biochem. 1994;31:497-500.
25. Prank K, Nowlan SJ, Harms HM et al. Time series prediction of plasma hormone concentration. Evidence for differences in predictability of parathyroid hormone secretion between osteoporotic patients and normal controls. J Clin Invest. 1995;95: 2910-2919.
26. Hollenberg AN, Arnold A. Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am J Med. 1991;91:547-548.
27. Brown EM, Pollak M, Seidman CE et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med. 1995;333:234-240.
28. Fuleihan G-H. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res. 2002;17 Suppl 2:N51-6.
29. Blind E, Raue F, Ziegler R. Rapid determination of serum intact parathyrin in hypercalcemic crisis, based on a commercially available kit. Clin Chem. 1990;36:387-388.
30. Gunn IR, Halkett JM. Rapid and accurate diagnosis of acute hyperparathyroid crisis [letter]. Lancet. 1989;2:618-619.
31. Nussbaum SR, Thompson AR, Hutcheson KA, Gaz RD, Wang CA. Intraoperative measurement of parathyroid hormone in the surgical management of hyperparathyroidism. Surgery. 1988; 104:1121-1127.
32. Bieglmayer C, Kaczirek K, Prager G, Niederle B. Parathyroid hormone monitoring during total parathyroidectomy for renal hyperparathyroidism: pilot study of the impact of renal function and assay specificity. Clin Chem. 2006;52:1112-1119.
33. Inabnet WB. Intraoperative parathyroid hormone monitoring. World J Surg. 2004;28:1212-1215.
34. Compston JE, Silver AC, Croucher PI, Brown RC, Woodhead JS. Elevated serum intact parathyroid hormone levels in elderly patients with hip fracture. Clin Endocrinol. 1989;31:667-672.
35. Mallette LE, Nammour H. False-positive elevations of midregional parathyroid hormone: inhibition of radioligand binding by a heterophilic antibody in patient serum. In: Cohn DV, Martin TJ, Meunier PJ, eds. Amsterdam: Excerpta Medica; 1987:550.
36. Simpson EL, Mundy GR, D'Souza SM, Ibbotson KJ, Bockman R, Jacobs JW. Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. N Engl J Med. 1983;309:325-330.
37. Schmelzer HJ, Hesch RD, Mayer H. Parathyroid hormone and PTH mRNA in a human small cell lung cancer. In: Havemann K, Sorenson G, Gropp C, eds. Berlin Heidelberg: Springer; 1985:88-93.
38. Yoshimoto K, Yamasaki R, Sakai H et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab. 1989;68:976-981.
39. Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med. 1990;323:1324-1328.
40. Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab. 1993;76: 1373-1375.
41. Blind E, Nissenson RA, Strewler GJ. Parathyroid hormone-related protein. In: Becker KL, ed. Philadelphia: Lippincott; 1995:467-474.
42. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997;138:4607-4612.
43. Lindsay R, Nieves J, Formica C et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550-555.
44. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med. 2001; 344:1434-1441.
45. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
46. Blind E. Introduction to the use of intact parathyroid hormone (PTH) determination. In: Schmidt-Gayk H, Blind E, Roth HJ, eds. Calcium regulating hormones and markers of bone metabolism: measurement and interpretation. Heidelberg: Clin Lab Publications; 1997:3-7.
47. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998;102:1627-1633.
48. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000;15:944-951.